Clareo Health | Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
This is a Phase 2a proof of concept study designed to evaluate the safety and efficacy of GSK933776 for the treatment of geographic atrophy secondary to age-related macular degeneration. This is a placebo-controlled parallel-group study that is double masked.
Age
55–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients ≥55 years of age inclusive
Evidence of AMD confirmed by the presence of at least 1 druse ≥125 μm diameter
Well-demarcated GA due to AMD of total area 1.9-17 mm2 measured in the study eye
Best-corrected visual acuity score of ≥ 35 letters (approximately 20/200 Snellen VA equivalent or better) in the study eye
You may not be if
Additional eye disease in the study eye that could compromise assessment of best-corrected visual acuity or imaging of the posterior pole
History of CNV secondary to AMD in the study eye
Any previous treatment for AMD in the study eye, approved or investigational, with the exception of dietary supplements
Risk of cerebrovascular disease, cerebral hemorrhage or stroke
History of systemic autoimmune disease
Use of platelet anti-aggregants or anti-coagulants (aspirin up to 325 mg/day is allowable, or in subjects allergic or intolerable to aspirin, clopidogrel up to 75 mg/day is allowable)
Use of chronic corticosteroids
Uncontrolled hypertension in spite of antihypertensive medications
Renal or hepatic insufficiency or clinically significant anemia
